Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
2.
Eur J Med Chem ; 45(12): 5958-64, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20970221

ABSTRACT

The main aim of this study was to enhance the solubility of pyrazolo[3,4-d]pyrimidines 1-8 able to strongly inhibit Src and Abl tyrosine kinase phosphorylation in cell-free assays and to significantly reduce leukemic and osteosarcoma cell lines growth, but characterized by very low solubility in aqueous media. Their water solubility was improved between 100 and 1000 folds by solubilization with 2-hydroxypropyl-ß-cyclodextrin (HPßCD) and ratio of inclusion complex were determined by phase solubility method. Finally, some complexed compounds were tested on different leukemic (K-652, KU-812 and HL-60) and osteosarcoma (SaOS-2) cell lines showing a good enhancement of biological response in comparison with the not complexed compounds.


Subject(s)
Antineoplastic Agents/pharmacology , Protein Kinase Inhibitors/pharmacology , Pyrazoles/pharmacology , Pyrimidines/pharmacology , beta-Cyclodextrins/chemistry , src-Family Kinases/antagonists & inhibitors , 2-Hydroxypropyl-beta-cyclodextrin , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Proliferation/drug effects , Drug Screening Assays, Antitumor , HL-60 Cells , Humans , Molecular Structure , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Pyrazoles/chemical synthesis , Pyrazoles/chemistry , Pyrimidines/chemical synthesis , Pyrimidines/chemistry , Solubility , Stereoisomerism , Structure-Activity Relationship , Tumor Cells, Cultured , Water/chemistry
3.
Nucleic Acids Res ; 37(11): 3660-9, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19369217

ABSTRACT

The HIV-1 accessory protein Vif plays a dual role: it counteracts the natural restriction factors APOBEC3G and 3F and ensures efficient retrotranscription of the HIV-1 RNA genome. We have previously shown that Vif can act as an auxiliary factor for HIV-1 reverse transcriptase (RT), increasing its rate of association to RNA or DNA templates. Here, by using seven different Vif mutants, we provide in vitro evidences that Vif stimulates HIV-1 RT through direct protein-protein interaction, which is mediated by its C-terminal domain. Physical interaction appears to require the proline-rich region comprised between amino acid (aa) 161 and 164 of Vif, whereas the RT stimulatory activity requires, in addition, the extreme C-terminal region (aa 169-192) of the Vif protein. Neither the RNA interaction domain, nor the Zn(++)-binding domain of Vif are required for its interaction with the viral RT. Pseudotyped HIV-1 lentiviral vectors bearing Vif mutants deleted in the RNA- or RT-binding domains show defects in retrotranscription/integration processes in both permissive and nonpermissive cells. Our results broaden our knowledge on how three important functions of Vif (RNA binding, RT binding and stimulation and Zn(++) binding), are coordinated by different domains.


Subject(s)
HIV Reverse Transcriptase/metabolism , vif Gene Products, Human Immunodeficiency Virus/chemistry , Cell Line , Humans , Mutation , Protein Binding , Protein Interaction Domains and Motifs , RNA/metabolism , Reverse Transcription , Virus Integration , Zinc Fingers , vif Gene Products, Human Immunodeficiency Virus/genetics , vif Gene Products, Human Immunodeficiency Virus/metabolism
4.
J Med Chem ; 51(21): 6635-8, 2008 Nov 13.
Article in English | MEDLINE | ID: mdl-18834110

ABSTRACT

HIV-1 replication has been inhibited by using a compound able to target the human cellular cofactor DEAD-box ATPase DDX3, essential for HIV-1 RNA nuclear export. This compound, identified by means of a computational protocol based on pharmacophoric modeling and molecular docking calculations, represents the first small molecule with such a mechanism of action and could lay the foundations for a pioneering approach for the treatment of HIV-1 infections.


Subject(s)
DEAD-box RNA Helicases/antagonists & inhibitors , DEAD-box RNA Helicases/metabolism , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , HIV-1/drug effects , HIV-1/enzymology , Virus Replication , Crystallography, X-Ray , DEAD-box RNA Helicases/chemistry , Drug Evaluation, Preclinical , Humans , Models, Molecular , Protein Structure, Tertiary
5.
Antiviral Res ; 76(2): 99-103, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17640745

ABSTRACT

The non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI)-binding pocket of HIV-1 RT spans codons 100-110, 180-190 and 220-240 and mutations in these domains are responsible for HIV-1 NNRTI resistance. Recombinant HIV-1 strains carrying G190S/A/E, G190S+T215Y, T215Y and K103N mutations were constructed to evaluate susceptibility to both NNRTIs and nucleoside RT inhibitors (NRTIs). In addition, purified recombinant RT enzymes were obtained to determine the degree of in vitro inhibition by drugs of both classes. High-level resistance to nevirapine and moderate level resistance to both stavudine and zidovudine were associated with G190S/A/E substitutions. The simultaneous presence of G190S and T215Y decreased stavudine and zidovudine susceptibility more than T215Y alone. On the other hand, G190S was associated with a marked decrease in RT catalytic efficiency, while T215Y showed a more limited effect. Interestingly, the simultaneous presence of G190S and T215Y was associated with a reduction in the impairment of the G190S-mutated enzyme. Mutations in the HIV-1 RT NNRTI binding pocket may be associated with cross-resistance to NRTI. Selection of double mutants, with further decrease in NRTI susceptibility, might be favoured by the compensatory effect of T215Y on the reduction of RT catalytic efficiency associated with G190S.


Subject(s)
Drug Resistance, Viral/genetics , HIV Reverse Transcriptase/genetics , HIV-1/drug effects , Mutation , Reverse Transcriptase Inhibitors/pharmacology , Stavudine/pharmacology , Zidovudine/pharmacology , Amino Acid Substitution , Anti-HIV Agents/pharmacology , HIV Reverse Transcriptase/isolation & purification , HIV Reverse Transcriptase/metabolism , HIV-1/genetics , Inhibitory Concentration 50 , Microbial Sensitivity Tests , Nevirapine/pharmacology
6.
Proteins ; 67(4): 1128-37, 2007 Jun 01.
Article in English | MEDLINE | ID: mdl-17357160

ABSTRACT

Human DDX3 (hDDX3) is a DEAD-box protein shown to possess RNA-unwinding and adenosine triphosphatase (ATPase) activities. The hDDX3 protein has been implicated in nuclear mRNA export, cell growth control, and cancer progression. In addition, a role of this protein in the replication of human immunodeficiency virus Type 1 and in the pathogenesis of hepatitis C virus has been recently proposed. Its enzymological properties, however, are largely unknown. In this work, we characterized its ATPase activity. We show that hDDX3 ATPase activity is stimulated by various ribo- and deoxynucleic acids. Comparative analysis with different nucleoside triphosphate analogs showed that the hDDX3 ATPase couples high catalytic efficiency to a rather relaxed substrate specificity, both in terms of base selection and sugar selection. In addition, its ability to recognize the L-stereoisomers of both 3' deoxy- and 2',3' dideoxy-ribose, points to a relaxed stereoselectivity. On the basis of these results, we hypothesize the presence of structural determinants on both the base and the sugar moieties, critical for nucleoside binding to the enzyme. Our results expand the knowledge about the DEAD-box RNA helicases in general and can be used for rational design of selective inhibitors of hDDX3, to be tested as potential antitumor and antiviral agents.


Subject(s)
Adenosine Triphosphatases/metabolism , DEAD-box RNA Helicases/metabolism , Nucleosides/metabolism , Adenosine Triphosphatases/antagonists & inhibitors , Adenosine Triphosphatases/genetics , Adenosine Triphosphatases/isolation & purification , DEAD-box RNA Helicases/antagonists & inhibitors , DEAD-box RNA Helicases/genetics , DEAD-box RNA Helicases/isolation & purification , Enzyme Activation/drug effects , Enzyme Inhibitors/pharmacology , Gene Expression , HeLa Cells , Humans , Hydrolysis , Kinetics , Magnesium/metabolism , Manganese/metabolism , Nucleic Acids/metabolism , Purine Nucleotides/pharmacology , Pyrimidine Nucleotides/pharmacology , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification , Recombinant Proteins/metabolism , Sensitivity and Specificity , Substrate Specificity
SELECTION OF CITATIONS
SEARCH DETAIL
...